Welcome to our dedicated page for Nautilus Biotechnolgy news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnolgy stock.
Nautilus Biotechnology, Inc., trading under the symbol NAUT, is a pioneering life sciences company based in Seattle, Washington, with research and development headquarters in San Carlos, California. The company is on a mission to revolutionize the field of proteomics by creating a platform technology designed to quantify and unlock the complexities of the human proteome. With this innovation, Nautilus aims to accelerate therapeutic development, enhance medical diagnostics, and promote personalized and predictive medicine.
The company’s core innovation is the Proteomic Analysis System, a single-molecule instrument prototype that offers unprecedented insights into the proteome. Nautilus brings together an extraordinary team of experts from diverse disciplines, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, and bioinformaticists. This multidisciplinary approach positions Nautilus to spearhead major advancements in drug development and human health management.
Nautilus has demonstrated significant progress in recent quarters, as highlighted by CEO Sujal Patel in their latest press release. Patel expressed excitement over the company's Q2 achievements, including the ability to integrate multiple platform elements such as sample preparation, affinity reagent probes, chips, flow cells, the instrument, multi-cycle assay, and software into a cohesive system. This development marks an essential step towards their commercial launch scheduled for next year.
Despite these ambitious projects, Nautilus maintains sound fiscal discipline, ensuring financial stability that extends operational funding through 2025 and into 2026. The company uses various channels to disclose material non-public information, including filings with the Securities and Exchange Commission, its website, press releases, public conference calls, public webcasts, and social media accounts.
Notably, Dr. Parag Mallick, a key visionary at Nautilus, was recently honored with the Computational Proteomics Award from US HUPO for his groundbreaking contributions to the field. Dr. Mallick's work in bioinformatics and computational methods has been instrumental in advancing proteomics research globally.
For investors and stakeholders keen on tracking the company's developments, Nautilus provides regular updates on their website and through investor relations contacts. To learn more about Nautilus Biotechnology, their mission, and their cutting-edge work in proteomics, visit their official website at www.nautilus.bio.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced it will release its second quarter 2022 financial results on August 2, 2022, before market open. A conference call will follow at 5:30 a.m. PT to discuss results, business developments, and future outlook. Nautilus is focused on developing a single-molecule protein analysis platform aimed at advancing proteomics for improved health and medicine.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported first-quarter financial results for 2022, revealing a net loss of $15.8 million, up from $8.4 million last year. Operating expenses surged by 90% to $16.0 million, primarily due to increased headcount and public company costs. Despite these financial setbacks, Nautilus highlighted significant scientific achievements, including advancements in single-molecule protein arrays and collaborations with Genentech. Cash reserves stood at $349.0 million as of March 31, 2022.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has announced the appointments of Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D. as Vice President of Affinity Reagent Development, enhancing its senior leadership team. Weld brings over 25 years of experience from companies like Microsoft and Amperity, focusing on building a high-performance culture. Dr. Wilcox joins from SomaLogic, where she developed critical proteomic technologies. These appointments are part of Nautilus's strategic expansion to advance its protein analysis platform, aimed at transforming healthcare diagnostics.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its financial results for Q1 2022 on May 3, 2022, before market opening. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET to discuss the results and business outlook. The event will be available for live audio streaming on the company’s investors' page. Nautilus is focused on advancing proteomics technology to enhance healthcare. For more information, visit www.nautilus.bio.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced key presentations at upcoming scientific conferences. Co-founder Parag Mallick, Ph.D., will present at the XIV Annual Congress of the European Proteomics Association in Leipzig, Germany, on April 6, 2022, discussing their novel single-molecule proteomics analysis platform. Associate Director Greg Kapp, Ph.D., will present a poster at the AACR Annual Meeting in New Orleans, LA, on April 13, 2022, focusing on protein identification techniques. These engagements highlight Nautilus' commitment to advancing proteomics and its potential impact on human health.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has appointed Karen Akinsanya, Ph.D., as a new member of its Board of Directors. Dr. Akinsanya brings over 25 years of experience in drug discovery, development, and commercialization. Currently serving as President of R&D at Schrödinger, she has a strong background in clinical pharmacology and business development from her tenure at Merck Research Laboratories. Her leadership is expected to enhance Nautilus’ strategy for the commercialization of its innovative protein analysis platform aimed at improving human health.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its fourth quarter and fiscal year 2021 results, highlighting key achievements and financial metrics. The company completed a business combination with ARYA Sciences Acquisition Corp III, generating approximately $345.5 million. Operating expenses soared 221% to $50.5 million, while net loss widened to $50.3 million from $15.6 million year-over-year. Nautilus announced collaborations with Amgen and MD Anderson, and a strategic partnership with Abcam. As of December 31, 2021, cash and investments totaled $362.1 million, supporting ongoing development.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate virtually in the 42nd Annual Cowen Health Care Conference on March 7th, 2022. The presentation is scheduled for 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties can access the live and archived webcast through Nautilus’ website.
Headquartered in Seattle, Nautilus is focused on developing a cutting-edge platform for detailed protein analysis, aiming to advance the field of proteomics and its applications in human health and medicine.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its financial results for Q4 and the full year 2021 before the market opens on February 24, 2022. The company's management will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss these results along with updates on business developments and future outlook. Audio of the webcast will be accessible in the 'Investors' section of the Nautilus website.
Nautilus is focused on developing a single-molecule protein analysis platform aimed at advancing proteomics and improving healthcare.
Nautilus Biotechnology (NASDAQ: NAUT) has announced a strategic partnership with Abcam to enhance its reagent development capabilities. This collaboration aims to accelerate R&D by utilizing Abcam's advanced monoclonal antibody technologies. The focus will be on developing affinity binding reagents for Nautilus' proteomic analysis system, followed by large-scale manufacturing and commercialization. This partnership is seen as a significant step toward improving drug and diagnostic tool development, enhancing the overall efficacy of Nautilus’ protein analysis platform.
FAQ
What is the current stock price of Nautilus Biotechnolgy (NAUT)?
What is the market cap of Nautilus Biotechnolgy (NAUT)?
What is Nautilus Biotechnology, Inc.?
What is the core technology developed by Nautilus Biotechnology?
Where is Nautilus Biotechnology headquartered?
What are the recent achievements of Nautilus Biotechnology?
Who is the CEO of Nautilus Biotechnology?
When will Nautilus's new platform be commercially launched?
How does Nautilus disclose important information?
Who was recently honored with the Computational Proteomics Award?
What is Nautilus's financial outlook?
Where can I find more information about Nautilus Biotechnology?
